NASDAQ:NKTR

Nektar Therapeutics Stock News

etoro logo Buy NKTR
*Your capital is at risk
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026

Where Nektar Therapeutics Stands With Analysts

06:02pm, Tuesday, 15'th Mar 2022 Benzinga
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 L

Where Nektar Therapeutics Stands With Analysts

06:02pm, Tuesday, 15'th Mar 2022 Benzinga
Nektar Therapeutics (NASDAQ: NKTR ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 Last 30D 0 0 2 0 0 1M Ago 0 1 0 1 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $10.5 versus the current price of Nektar Therapeutics at $4.285, implying upside. Below is a summary of how these 4 analysts rated Nektar Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the … Full story available on Benzinga.com

Nektar draws more downgrades after setback for melanoma trial

03:58pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Clinical-stage biotech Nektar Therapeutics (NKTR) is trading higher on Tuesday after losing over half of its market cap yesterday in reaction to its failure to reach the main goals in…
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the fourth quarter, compared
Tuesday afternoon''s top analyst upgrades and downgrades included Coupa Software, GoodRx, Mosaic and Nektar Therapeutics.

Nektar (NKTR) Plunges on Bempeg's Melanoma Study Failure

02:38pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.
Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.

10 Biggest Price Target Changes For Tuesday

11:52am, Tuesday, 15'th Mar 2022 Benzinga
Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading. Credit Suisse raised HollyFrontier
Markets edged higher to start off Tuesday, as West Texas Intermediate crude slid below the $100 mark.
Fintech stocks fell on reports of a troubled securities sale from AFRM. BRK.A tested the $500K mark and hit a new high. GME fell to a new low. NKTR plunged on clinical data. TRQ rallied.

Why Nektar Therapeutics Stock Is Imploding Today

04:01pm, Monday, 14'th Mar 2022 The Motley Fool
A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.

Why Nektar Therapeutics Stock Is Imploding Today

04:01pm, Monday, 14'th Mar 2022 The Motley Fool
A clinical trial readout involving the company''s lead candidate didn''t produce the results investors were hoping for.
Bristol Myers Squibb Co (NYSE: BMY ) and Nektar Therapeutics (NASDAQ: NKTR ) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma patients. The review by an independent Data Monitoring Committee (DMC) suggested that the study did … Full story available on Benzinga.com
Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter, compared to $2.39 in
Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE: ENVA ) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter, compared to $2.39 in the year-ago quarter. The stock has a 52-week-high of $47.88 and a 52-week-low of $30.04. At the end of the last trading period, Enova International closed at $33.50. Seaport Global upgraded the previous rating for Helmerich & Payne Inc (NYSE: HP ) from Neutral to Buy. For the first quarter, Helmerich & Payne had an EPS of $0.45, compared to year-ago quarter EPS of $0.82. The stock has a 52-week-high of $45.40 and a 52-week-low of $20.93. At the end of the last trading period, Helmerich & Payne closed at $41.88. According to Berenberg, the prior rating for Deutsche Bank AG (NYSE: DB ) was changed from Sell to Hold. For the fourth quarter, Deutsche Bank had an EPS of $0.14, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $16.70 and a 52-week-low of $9.46. At the end of the last trading period, Deutsche Bank closed at $10.25.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE